| 1. |
|
|
| 2. |
- Johansson, Boo, et al.
(författare)
-
Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people
- 2004
-
Ingår i: European Journal of Pharmacology. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 60:1, s. 45-49
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVES: Elevated plasma homocysteine might indicate an increased risk of cancer, and cardiovascular and neurological diseases. The homocysteine level depends on the supply of folate and cobalamine, and constipation and/or laxative treatment might compromise this supply. The present study examined the impact of constipation and laxative treatment on the blood levels of homocysteine, folate and cobalamine in a population-based sample of aged people, including consideration of frailty and impaired renal function, both of which may also influence the homocysteine level. METHODS: The study was based on biochemical tests in 341 females and 183 males aged 82 years or older. The concentrations of homocysteine (plasma), folate, cobalamine and urea (serum) were measured in subjects with and without ongoing treatment with laxative drugs. Values were adjusted for age, gender and frailty, as well as for clinical diagnoses and drug therapies known to affect homocysteine levels. RESULTS: Homocysteine levels were increased and those of folate reduced in aged subjects on laxatives. Homocysteine remained elevated after adjusting for frailty and various neurological disorders. There was no significant effect on homocysteine and folate in constipated subjects without laxatives
|
|
| 3. |
- Nilsson, SE, et al.
(författare)
-
Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged >= 80 years
- 2003
-
Ingår i: European Journal of Clinical Pharmacology. - : Springer Science and Business Media LLC. - 1432-1041 .- 0031-6970. ; 59:4, s. 313-319
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis after stroke and transient ischaemic attacks, conditions that may obscure an anti-dementia effect by the drug. Alternatively, low-dose aspirin may be insufficient if the protective effect is due to an anti-inflammatory mechanism. The aim of this study was to assess whether high-dose or low-dose aspirin may protect against Alzheimer's dementia in subjects aged greater than or equal to80 years. For comparison, effects of (other) NSAID, paracetamol and D-propoxyphene were studied. Methods. Global, cross-sectional, and longitudinal (1991-2000) epidemiological analyses of clinical, cognitive and drug treatment data on 702 individuals 80 years old or more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years (80-99 years). Calculations were made with logistic regression of associations between use of various analgesics and cognitive function, after adjustment for age, gender, and cardiovascular and cerebrovascular diseases. Results. Users of high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and better-maintained cognitive function than non-users. There were numerically similar but not significant associations with use of low-dose aspirin and other NSAID. There were no such associations with use of either paracetamol or D-propoxyphene. Conclusion. Aspirin might protect against Alzheimer's disease, but controlled trials are warranted.
|
|
| 4. |
|
|
| 5. |
|
|
